Prolonged low intensity EPOCH–rituximab has improved toxicity in Burkitt lymphoma compared with standard short, high intensity therapy

Burkitt lymphoma is an aggressive form of non-Hodgkin lymphoma that has a short doubling time, thus intense short-cycle chemotherapy has been thought to be essential. A recent NCI-sponsored clinical trial investigated DA-EPOCH-R given to 19 HIV-negative patients and a short course regimen (SC-EPOCH-...

Full description

Saved in:
Bibliographic Details
Main Authors: Shahbazi, Shandiz, Peer, Cody J, Figg, William D
Format: Artigo
Language:Inglês
Published: Landes Bioscience 2014
Subjects:
Commentary
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC4128854/
https://ncbi.nlm.nih.gov/pubmed/24919059
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4161/cbt.29504
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items